Skip to main content
. 2020 Oct 31;8:83. doi: 10.1186/s40560-020-00500-0

Fig. 5.

Fig. 5

Trial sequential analysis for 28-day mortality. Heterogeneity adjusted required information size of 5040 patients calculated on basis of proportion of 28-day mortality of 38.26, 42.13% in the non-catecholamine vasopressors and norepinephrine group, respectively (α = 5%, β = 20%, I2 = 0%)